| Date |
Subject |
Media |
| 2025-09-10 |
TaiMed Biologics Driven by Three Growth Engines; CEO: Major Business Transformation Expected by 2026
|
TaiMed Biologics CEO Jin-Mei Chang said on August 22 that the company is focused on three major growth drivers: rising sales of Trogarzo and expanding CDMO revenues, accelerated Phase II clinical development and licensing of its next-generation HIV therapies TMB-365/TMB-380, and advances in its antibody-drug conjugate (ADC) platform. He projected that 2026 will mark a turning point for the company’s operations. |
| 2025-09-10 |
ABC-KY Posts NT$1 Loss Per Share in H1; New Diagnostic Target Expected to Enter Major Clients by Year-End
|
Applied Biocode Corp. (ABC-KY) reported nearly 30% year-on-year revenue growth in the first half of 2025 but still posted a net loss of NT$103 million, equivalent to a loss of NT$1 per share. Management noted that a leading U.S. molecular diagnostics laboratory will begin adopting more of the company’s flagship products in the second half, alongside phased purchases of multiple MDx3000 fully automated molecular diagnostic systems, expected to provide significant growth momentum. Its new “STI+AMR” (Sexually Transmitted Infections plus Antimicrobial Resistance) assay is currently undergoing testing with three major clients and could enter routine clinical use before the end of the year. |
| 2025-09-10 |
Luo Lih-Fen Holding Q2 Gross Margin Surges, EPS at NT$1.38 Marks 18-Quarter High, Three Channels Drive Strong Outlook for H2
|
Beauty channel operator Luo Lih-Fen Holding (羅麗芬-KY) saw simultaneous growth across its three major sales channels in the first half of the year, driving a sharp rebound in Q2 profitability. Gross margin jumped to 69.61%, up 6 percentage points year-on-year and 9 percentage points quarter-on-quarter, boosting core earnings. Earnings per share (EPS) reached NT$1.38, the highest in 18 quarters. Looking ahead, the company is targeting e-commerce demand during the “Double 11” shopping season, launching three new products under its namesake skincare brand in Q4. Combined with the opening of more community-based stores and seasonal demand in the second half, operations are expected to outperform the first half. |
| 2025-09-10 |
Genomics BioSci & Tech. Chairman Michael Chou Rallies Partners to Drive AI-Powered Drug Development
|
The global boom in AI applications is reshaping the biotechnology and healthcare industries, with AI increasingly being used to accelerate drug discovery and development. This shift has fueled a wave of new strategic alliances. Genomics BioSci & Tech. (Genomics) entered the U.S. market in 2023 through its investment in Wyzer, and in 2024, it raised capital for its subsidiary LAI SHI TE SHENG YI, bringing in strategic investors to speed up new drug development. In July this year, Chairman Michael Chou (周孟賢) personally attended a forum announcing a strategic alliance with BIONET Corp., highlighting his determination to accelerate Genomics’ diversification and global expansion. |
| 2025-09-10 |
Core Business and Non-Operating Gains Boost CHLITINA HOLDING LIMITED’s Q2 EPS to NT$2.62, Up 285% Quarter-on-Quarter
|
CHLITINA HOLDING LIMITED (CHLITINA-KY) reported that thanks to growth in its core business and non-operating financial subsidies totaling RMB 18 million, its Q2 operating profit reached NT$147 million, up 54% quarter-on-quarter. Net profit attributable to the parent company was NT$216 million, representing a 285% quarterly increase, with earnings per share (EPS) of NT$2.62. For the first half of the year, net profit attributable to the parent company totaled NT$272 million, with an EPS of NT$3.3. |
| 2025-09-10 |
TCI’s Asset-Light Expansion Moves into Spain: New Equipment in Place, Tariff Impact Eases, H2 Performance Set to Strengthen
|
Vincent Lin, Chairman of TCI, stated yesterday (21st) that the company has successfully entered the top three global pharmaceutical companies, the top three U.S. direct selling companies, and major international internet giants, marking its transformation into a truly global enterprise operating simultaneously across the U.S., Europe, and Asia-Pacific. To support this expansion, TCI is advancing its “asset-light strategy” and is currently evaluating the establishment of a production base in Spain. |
| 2025-09-10 |
Orient Pharma Expands International Footprint with ADHD Drug Push
|
OEP Group’s biotech subsidiary Orient Pharma was listed on the Taipei Exchange on the 21st. Chairman Tsai, Cheng-Hung stated that the company will continue to capitalize on patent expirations and market gaps, leveraging its core technology platforms to build a differentiated product portfolio and enhance global competitiveness. |
| 2025-09-10 |
MAXIGEN BIOTECH Launches U.S. Investment, Targeting Opportunities in Healthy Ageing and Regenerative Medicine
|
MAXIGEN BIOTECH is accelerating its global transformation from a manufacturer to a branded company. General Manager Ching-Ting Chen stated that the company aims to increase its brand-driven revenue contribution from the current 60% to 80% by 2030. This year, it will establish a U.S. subsidiary for business operations, with medium- to long-term manufacturing also planned to move to the United States. |
| 2025-09-10 |
TTY Biopharm’s Three-Pronged Growth Strategy Continues; Second-Half Revenue Expected to Surpass First Half
|
TTY Biopharm posted record-high revenue and operating profit in the first half of 2025, with EPS at NT$2.72. At the company’s investor conference on the 20th, General Manager Sara Hou said TTY’s “three-pronged strategy” continues to advance. Its complex generic drug Lipo-AB is achieving new sales highs in the U.S., shipments of its cell-based influenza vaccine are expected to rise further, and its breast cancer hormone therapy obtained a new second-line combination CDK4/6 indication this July. The company also expects Taiwan’s first domestically developed lung cancer drug to receive approval in the fourth quarter. Over the next three years, three additional products are slated for launch. Analysts expect second-half revenue to exceed the first half, with full-year revenue growth in the high single-digit to double-digit range. |
| 2025-09-10 |
FORMOSA BIOMEDICAL TECHNOLOGY Partners with UWELL Biopharma to Build Next-Generation CAR-T Commercial Production Model
|
Formosa Biomedical Technology, a subsidiary of Formosa Plastics Group, has been diversifying its business in recent years. On the 20th, it jointly announced with UWELL Biopharma a collaboration to advance the clinical development and commercialization of next-generation CAR-T cell therapy. UWELL’s anti-CD19 CAR-T therapy candidate, UWC19, is scheduled to begin a multicenter Phase II clinical trial in the fourth quarter of this year. Formosa Biomedical Technology will leverage its strengths in drug formulation and production to support the effort, aiming to bring Taiwan’s advanced cell therapy industry onto the global stage. |
